Oxford University coronavirus vaccine trial prompts immune r
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
The covid-19 vaccine being developed by Oxford University and AstraZeneca, ChAdOx1 nCoV-19, generated an immune response in a study of roughly 1,000 patients, according to interim results published in the medical journal the Lancet on 20 July.

Key Insights:

• The experimental vaccine produced a dual immune response in people aged 18 to 55 that lasted at least two months after they were immunized.

• The vaccine was safe and tolerated, with reduced reactogenicity when paracetamol was used prophylactically for the first 24 h after vaccination.

• Humoral responses to SARS-CoV-2 spike protein peaked by day 28 post-prime and cellular responses were induced in all participants by day 14.

• Neutralising antibodies were induced in all participants after a second vaccine dose.

• After two doses, potent cellular and humoral immunogenicity were present in all participants studied.

• However, the vaccine, called AZD1222, requires larger trials to test whether it can offer protection against coronavirus.

• Britain has already secured a supply of 100 million doses of the vaccine, which is being developed at an unprecedented speed.

1. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31604-4/fulltext
2. https://www.mercurynews.com/2020/07/20/uk-coronavirus-vaccine-prompts-immune-response-in-early-test/
m●●●●●●i s●●●●●●a and 19 others like this6 shares